PhoreMost Ltd

26 articles with PhoreMost Ltd

• 

  BioSpace Global Roundup: June 27

  6/27/2019

  Biotech and pharma companies from across the globe share pipeline and business updates.

• Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target

  6/12/2019

  Ligand will now apply its Vernalis Design Platform (VDP) to design small molecule inhibitors against the target, to help rapidly progress compounds through hit-to-lead and lead optimization stages.

• PhoreMost and o2h discovery collaborate to progress first-in-class drug discovery programs

  6/21/2018

  The collaboration will see o2h deploy its expertise in medicinal chemistry to help progress PhoreMost’s portfolio rapidly through the hit-to-lead and lead-optimisation stages of drug discovery.

• PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore, an Immuno-Oncology Company

  11/15/2017

  Sixth Element Capital LLP announces a £3 million investment in NeoPhore, a spin out from Cambridge, UK based PhoreMost Ltd

• PhoreMost Ltd And University of Cambridge Collaborate To Identify Innovative Drug Targets For Neurodegenerative Disease

  10/12/2016

• PhoreMost Ltd And The Wistar Institute Collaborate To Identify New Druggable Targets In Cancer, Immunotherapy And Aging

  3/10/2016